Understanding cancer risk related to TP53 gene changes
Precision approaches to refining TP53-associated cancer risk
This study is looking at how changes in the TP53 gene might affect cancer risk for people with Li-Fraumeni Syndrome, helping to better understand who might be at higher risk and how to tailor cancer screenings and prevention for them, especially for older adults who have had chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10693974 on NIH RePORTER |
What this research studies
This research investigates the role of TP53 gene variants in increasing cancer risk, particularly in individuals with Li-Fraumeni Syndrome, a hereditary condition linked to multiple cancers. By utilizing advanced genetic testing methods, the study aims to identify and differentiate between true germline mutations and acquired variants that may not pose the same risks. The goal is to improve the understanding of cancer predisposition and provide better risk assessment for patients, especially older adults who may have been exposed to chemotherapy. This research could lead to more personalized cancer screening and prevention strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of Li-Fraumeni Syndrome or those who have undergone genetic testing revealing TP53 variants.
Not a fit: Patients without any known TP53 gene variants or those not at risk for hereditary cancer syndromes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer risk assessment and tailored prevention strategies for individuals with TP53 mutations.
How similar studies have performed: Previous research has shown promising results in understanding the implications of TP53 mutations, indicating that this approach has potential for significant advancements in cancer risk assessment.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Gruber, Stephen B — Beckman Research Institute/city of Hope
- Study coordinator: Gruber, Stephen B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.